

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* Whitehead Warren			2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/23/2020					
C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(Street) TORONTO, A6 M2J 4R3								
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	06/23/2020		M		1,250	A	\$ 1.91 (1)	51,250	D	
Common Shares	06/23/2020		M		500	A	\$ 1.6 (2)	51,750	D	
Common Shares	06/23/2020		M		1,250	A	\$ 4.22 (3)	53,000	D	
Common Shares	06/23/2020		M		10,000	A	\$ 1.12 (4)	63,000	D	
Common Shares	06/23/2020		S		13,000	D	\$ 7.08 (7)	50,000	D	
Common Shares	06/23/2020		S		5,000	D	\$ 7.17 (8)	45,000	D	
Common Shares	06/24/2020		M		5,000	A	\$ 1.02 (5)	50,000	D	
Common Shares	06/24/2020		M		7,000	A	\$ 2.6 (6)	57,000	D	
Common Shares	06/24/2020		S		12,000	D	\$ 6.73 (9)	45,000	D	
Common Shares	06/24/2020		S		5,000	D	\$ 6.78 (10)	40,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Director Stock Option (Right to Buy)	\$ 1.91 (1)	06/23/2020		M		1,250		11/29/2011	11/29/2021	Common Shares	1,250	\$ 0	0	D	

Director Stock Option (Right to Buy)	\$ 1.6 ⁽²⁾	06/23/2020		M	500	03/09/2012	03/09/2022	Common Shares	500	\$ 0	0	D
Director Stock Option (Right to Buy)	\$ 4.22 ⁽³⁾	06/23/2020		M	1,250	11/29/2011	11/29/2021	Common Shares	1,250	\$ 0	0	D
Director Stock Option (Right to Buy)	\$ 1.12 ⁽⁴⁾	06/23/2020		M	10,000	03/28/2017	03/28/2027	Common Shares	10,000	\$ 0	0	D
Director Stock Option (Right to Buy)	\$ 1.02 ⁽⁵⁾	06/24/2020		M	5,000	06/06/2017	06/06/2027	Common Shares	5,000	\$ 0	0	D
Director Stock Option (Right to Buy)	\$ 2.6 ⁽⁶⁾	06/24/2020		M	7,000	01/19/2018	01/19/2028	Common Shares	7,000	\$ 0	53,000	D

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Whitehead Warren C/O APTOSE BIOSCIENCES INC. 251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3	X			

Signatures

/s/ Gregory K. Chow as attorney-in-fact for Warren Whitehead		06/25/2020
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Converted from Canadian exercise price of \$2.58 using an exchange rate of 1.3516.

(2) Converted from Canadian exercise price of \$2.16 using an exchange rate of 1.3516.

(3) Converted from Canadian exercise price of \$5.70 using an exchange rate of 1.3516.

(4) Converted from Canadian exercise price of \$1.52 using an exchange rate of 1.3516.

(5) Converted from Canadian exercise price of \$1.38 using an exchange rate of 1.3516.

(6) Converted from Canadian exercise price of \$3.52 using an exchange rate of 1.3516.

(7) The sale price of \$7.08 is a weighted average price. These shares were sold in multiple transactions at prices ranging from C\$9.55 to C\$9.6464, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7). The average weighted sale price of C\$9.57 was converted into U.S. dollars using an exchange rate of 1.3516.

(8) Converted from Canadian sale price of \$9.69 using an exchange rate of 1.3516.

(9) The sale price of \$6.73 is a weighted average price. These shares were sold in multiple transactions at prices ranging from C\$9.00 to C\$9.22, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9). The Canadian average weighted sale price of \$9.09 was converted to U.S. dollars using an exchange rate of 1.3516.

(10) Converted from Canadian sales price of \$9.1678 using an exchange rate of 1.3516.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.